Novo Nordisk's sought-after obesity therapy Wegovy has finally reached the UK and can be prescribed by NHS weight management services – but supplies are being carefully co
Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 milli
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.
